How Much Does Belsomra (Suvorexant) Cost in Mississippi in 2026?

Mississippi Retail Pricing: Cash-Pay vs. List Price

The gap between what Merck charges and what Mississippi patients actually pay is significant. Merck's wholesale acquisition cost (WAC) for Belsomra sits at $340 per month for a 30-count supply. That figure rarely reflects what patients hand over at the pharmacy counter.

Across Mississippi retail pharmacies in 2026, the average cash-pay price for a 30-day supply of Belsomra lands around $85. This discount comes from pharmacy benefit managers (PBMs), manufacturer rebates, and competitive pricing among chains like Walgreens, CVS, and independent pharmacies throughout Jackson, Gulfport, Hattiesburg, and other Mississippi cities. Prices can vary by $20 to $40 depending on the specific pharmacy and whether patients use a discount card from services like GoodRx or RxSaver.

The FDA-approved prescribing information for Belsomra lists four dose strengths: 5 mg, 10 mg, 15 mg, and 20 mg. All four strengths carry the same list price. The recommended starting dose is 10 mg, with the option to increase to 20 mg if 10 mg is tolerated but not effective. Patients taking moderate CYP3A inhibitors should start at 5 mg. These dosing details matter for cost planning because each dose tier is priced identically at retail.

Mississippi Medicaid Does Not Cover Belsomra

Mississippi's Medicaid program, administered through the Division of Medicaid under the Mississippi Department of Human Services, does not include Belsomra on its preferred drug list. This means the roughly 780,000 Mississippians enrolled in Medicaid cannot access suvorexant through their state benefit without a prior authorization process that rarely results in approval for this particular medication.

Mississippi Medicaid does cover several alternative insomnia treatments, including generic zolpidem (Ambien), generic eszopiclone (Lunesta), and generic trazodone. A prescriber who believes suvorexant is medically necessary for a Medicaid patient can submit a prior authorization request citing clinical failure of preferred agents. The American Academy of Sleep Medicine's 2017 clinical practice guideline recommends suvorexant as one of several pharmacologic options for sleep-onset and sleep-maintenance insomnia in adults, which can support such requests. Approval rates for non-preferred sleep medications through Mississippi Medicaid remain low.

For patients whose Medicaid prior authorization is denied, the appeal process goes through the Division of Medicaid's Fair Hearing process. A supporting letter from the prescribing physician documenting failed trials of at least two preferred agents strengthens the case.

Private Insurance Coverage in Mississippi

Commercial insurance plans in Mississippi vary widely in their treatment of Belsomra. The largest insurers operating in the state include Blue Cross Blue Shield of Mississippi, UnitedHealthcare, Humana, Aetna, Cigna, and Ambetter (managed by Centene). Each maintains its own formulary.

Blue Cross Blue Shield of Mississippi, which covers more residents than any other private insurer in the state, typically places Belsomra on Tier 3 (non-preferred brand). This means copays generally range from $50 to $75 per month, depending on the specific plan. Most BCBS MS plans require step therapy, meaning the patient must try and fail a generic sleep aid before Belsomra is approved.

UnitedHealthcare and Cigna plans sold in Mississippi often classify Belsomra as Tier 3 as well, with similar step-therapy requirements. Humana Medicare Advantage plans, popular among Mississippi's older population, may cover Belsomra but frequently impose quantity limits of 30 tablets per 30 days and prior authorization.

The key strategy for any Mississippi patient: call the number on the back of your insurance card and ask three specific questions. Is suvorexant on my formulary? What tier? What are the step-therapy or prior authorization requirements? These answers determine the real out-of-pocket cost far more precisely than any general estimate.

The Merck Savings Card: How It Works in Mississippi

Merck offers a manufacturer savings card for Belsomra that can reduce out-of-pocket costs for commercially insured patients. The card is not available to patients with government insurance, including Medicaid, Medicare, Tricare, or VA benefits.

Eligible Mississippi patients with commercial insurance can use the Merck savings card to pay as little as $0 to $30 per month for Belsomra, depending on their plan's copay structure. The card typically covers up to $75 per prescription fill, with a maximum annual benefit. Patients can enroll online through Merck's patient assistance portal or receive a card from their prescriber's office.

There are limits. The savings card has an annual cap, usually around $900 per year. Once that cap is reached, the patient reverts to their plan's standard copay. The card also cannot be combined with other manufacturer coupons. For uninsured Mississippi patients, Merck's separate patient assistance program (Merck Helps) provides Belsomra at no cost to qualifying households earning below 400% of the federal poverty level.

Compounded Suvorexant in Mississippi: Legal Status and Access

Compounded suvorexant is available in Mississippi through 503A-licensed compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on individual patient prescriptions. Mississippi's Board of Pharmacy regulates these facilities under Mississippi Code Title 73, Chapter 21.

A compounded version of suvorexant may be prescribed when a physician determines the commercially available formulation is not appropriate. For example, a patient who needs a non-standard dose (such as 7.5 mg) or who cannot swallow tablets might benefit from a compounded liquid suspension. The compounded product is not an FDA-approved generic; it is prepared from bulk pharmaceutical-grade suvorexant powder by a licensed compounding pharmacist.

Pricing for compounded suvorexant in Mississippi varies by pharmacy but can be substantially lower than brand-name Belsomra. Some 503A pharmacies offer compounded suvorexant for minimal dispensing fees when patients work with telehealth platforms that have established compounding relationships. Patients should confirm that any compounding pharmacy they use holds both a valid Mississippi Board of Pharmacy license and appropriate DEA registration, since suvorexant is a Schedule IV controlled substance.

One clinical consideration: the Herring et al. Key trial published in Lancet Neurology (2014, N=250) established suvorexant's efficacy at doses of 10 mg, 20 mg, and 40 mg (the 40 mg dose was not approved), showing statistically significant improvements in both subjective total sleep time and wake after sleep onset compared to placebo. That trial used the brand-name formulation. Compounded versions have not undergone the same bioequivalence testing, though USP standards govern their preparation.

Telehealth Prescribing of Belsomra in Mississippi

Mississippi permits telehealth prescribing of Belsomra. The Mississippi State Board of Medical Licensure adopted permanent telehealth regulations following the expanded access provisions during the COVID-19 public health emergency. Mississippi Code Section 83-9-351 requires insurers to cover telehealth services on par with in-person visits.

For Schedule IV controlled substances like suvorexant, Mississippi follows the federal Ryan Haight Act requirements. A prescriber must conduct an initial evaluation (which can be via real-time audio-video telehealth) before issuing a prescription. Follow-up prescriptions can be managed through subsequent telehealth appointments.

This opens access for patients in Mississippi's rural counties where sleep medicine specialists are scarce. According to the Mississippi State Department of Health, the state has fewer than 30 board-certified sleep medicine physicians, concentrated in Jackson, the Gulf Coast, and the Oxford-Tupelo corridor. Telehealth platforms can connect patients in the Delta region, Pine Belt, and other underserved areas with prescribers who can evaluate, diagnose, and prescribe suvorexant without requiring a multi-hour drive.

Mississippi patients using telehealth for Belsomra should verify that their prescriber holds an active Mississippi medical license and that the telehealth platform's affiliated pharmacy can dispense Schedule IV medications to Mississippi addresses.

How Suvorexant Compares to Other Insomnia Drugs on Cost

Belsomra's $85 average cash price in Mississippi sits between the cheapest generics and the most expensive branded alternatives. Context helps.

Generic zolpidem (Ambien) costs $8 to $15 per month at most Mississippi pharmacies. Generic eszopiclone runs $12 to $25. Trazodone, used off-label for insomnia, costs under $10. These are the first-line options most Mississippi insurers and Medicaid will approve.

On the expensive end, lemborexant (Dayvigo), another dual orexin receptor antagonist in the same class as suvorexant, carries a list price of approximately $400 per month. Quviviq (daridorexant), the newest DORA, lists at roughly $450. Neither has a generic available.

The clinical question is whether suvorexant offers advantages that justify its higher cost compared to generics. The 2014 Herring et al. Trial demonstrated that suvorexant 20 mg improved subjective total sleep time by a mean of 22 minutes over placebo at week 4 (P<0.001). A 2020 network meta-analysis published in the Journal of Clinical Sleep Medicine found that DORAs as a class had a lower risk of next-day residual sedation compared to benzodiazepine receptor agonists like zolpidem.

For Mississippi patients weighing cost against clinical profile: suvorexant's mechanism (blocking wakefulness-promoting orexin signals rather than broadly sedating) may be preferable for those who have experienced parasomnias, next-day impairment, or dependence concerns with Z-drugs. The FDA's 2014 approval review noted that suvorexant showed no evidence of rebound insomnia after discontinuation in clinical trials, a meaningful distinction from some GABA-acting agents.

Specific Strategies to Lower Belsomra Costs in Mississippi

Patients and prescribers in Mississippi have several concrete approaches to reduce suvorexant costs.

Dose-splitting with prescriber approval. Belsomra 20 mg tablets cost the same as 10 mg tablets. A prescriber can write for 20 mg tablets with instructions to split them, effectively halving the per-dose cost. This only works with the 20 mg strength, as the 10 mg tablets are smaller and harder to split accurately. Patients should use a proper pill splitter.

Pharmacy shopping. Mississippi prices vary. A patient in Jackson might find Belsomra for $72 at a Costco pharmacy (no membership required for pharmacy services in Mississippi) while a CVS across town charges $95. Checking three pharmacies takes 15 minutes and can save $20 or more per fill.

90-day fills. Many Mississippi pharmacies and mail-order services offer a discount for 90-day supplies, typically charging the equivalent of 2.5 months rather than 3. For a medication taken nightly long-term, this adds up.

Manufacturer assistance. Beyond the savings card, Merck Helps provides free Belsomra to uninsured patients earning under 400% FPL. A single Mississippian earning under $58,320 (2026 guidelines) qualifies. The application requires income verification and a valid prescription.

Compounding. As noted, 503A pharmacies in Mississippi can prepare suvorexant at lower cost for patients with valid prescriptions. This route is particularly cost-effective when combined with telehealth platforms that have negotiated compounding rates.

What the Pipeline Holds: Generic Suvorexant Timeline

Merck's core patents on suvorexant extend through the mid-2030s. The compound patent (US Patent 8,003,647) and several formulation patents protect the drug from generic competition. No ANDA (Abbreviated New Drug Application) for generic suvorexant has been approved by the FDA as of May 2026.

This means Mississippi patients should not expect a dramatic price drop from generic entry for several more years. The compounding route through 503A pharmacies remains the primary alternative for patients seeking lower-cost suvorexant specifically. For patients open to a different medication in the same class, monitoring the patent field of lemborexant and daridorexant may reveal earlier generic opportunities, though neither is imminent.

The Endocrine Society's approach to cost-conscious prescribing recommends that clinicians discuss medication costs openly with patients and consider therapeutic alternatives when cost is a barrier to adherence. This principle applies directly to insomnia management in Mississippi, where per-capita income ($28,990 in 2024 Census estimates) ranks among the lowest nationally.

Mississippi-Specific Pharmacy Resources

Mississippi residents can access the Mississippi State Board of Pharmacy's licensee verification tool to confirm that any compounding pharmacy holds valid credentials. The Board's enforcement division investigates complaints about compounding quality or unlicensed activity.

For Medicare Part D enrollees, the Medicare Plan Finder allows Mississippi residents to compare formularies by zip code during open enrollment (October 15 through December 7). Several Part D plans in Mississippi cover Belsomra at Tier 3, with monthly copays ranging from $42 to $95 depending on the specific plan and coverage phase.

Mississippi's two Federally Qualified Health Center networks, Delta Health Alliance and Aaron E. Henry Community Health Services Center, offer sliding-scale pharmacy services that can reduce costs for qualifying patients. Patients in the Mississippi Delta region, where pharmacy deserts are common, may benefit from mail-order options that accept manufacturer savings cards.